Aims To examine associations of the gut microbial metabolite trimethylamine-N-oxide
(TMAO) and its precursors with risk of cardiovascular events in acute coronary syndrome …

The gut metabolite trimethylamine N-oxide (TMAO) at admission has a prognostic value in
ST-elevation myocardial infarction (STEMI) patients. However, its sequential changes and …

Trimethylamine-N-oxide (TMAO) is a uremic toxin, which has been associated with chronic
kidney disease (CKD). Renal tubular epithelial cells play a central role in the …

Chronic kidney disease is considered as a serious obstacle in global health, with increasing
incidence and prevalence. In spite of numerous attempts by using recent omics …

Background/objective There is evidence that metabolic profile changes after Roux-Y gastric
bypass (RYGB), especially due to modifications in the gastrointestinal tract. In addition …

Background. Due to the critical shortage of kidneys for transplantation, the identification of
modifiable factors related to graft failure is highly desirable. The role of trimethylamine-N …

Objective This study aimed to evaluate the effect of trimethylamine oxide (TMAO) on the
incidence and prognosis of cerebral infarction. Methods We searched PubMed, Embase …

Background: Trimethylamine N-Oxide (TMAO), as a gut microbiota-derived metabolite, has
been associated with a number of chronic diseases like cardiovascular diseases. Objective …

Abstract Trimethylamine-N-oxide (TMAO) gained considerable attention because of its role
as a cardiovascular risk biomarker. Organic cation transporter 2 (OCT2) mediates TMAO …

Introduction Type 2 diabetes mellitus (T2D) confers high atherosclerotic cardiovascular
disease (ASCVD) risk. The metabolite trimethylamine N-oxide (TMAO) derived via gut flora …